Loss of RASSF1A expression in colorectal cancer and its association with k-ras status

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Cao, Dan ^a   Chen, Ye ^a   Tang, Yuan ^a   Peng, Xing Chen ^a   Dong, Hang ^a   Li, Long Hao ^a   Cheng, Ke ^a   Ge, Jun ^a   Liu, Ji Yan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADENOMA; ADULT; AGED; ARTICLE; CANCER STAGING; COLON; COLORECTAL CANCER; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUCOSA; PROTEIN EXPRESSION; RECTUM; COLORECTAL TUMOR; GENETICS; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; VERY ELDERLY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 84880170991     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/976765     Document Type: Article

References (31)

1. Fang J. Y., Richardson B. C., The MAPK signalling pathways and colorectal cancer. The Lancet Oncology 2005 6 5 322 327 2-s2.0-17844368327 10.1016/S1470-2045(05)70168-6
2. Ahlquist T., Bottillo I., Danielsen S. A., Meling G. I., Rognum T. O., Lind G. E., Dallapiccola B., Lothe R. A., RAS signaling in colorectal carcinomas through alterations of RAS, RAF, NF1, and/or RASSF1A. Neoplasia 2008 10 7 680 686 2-s2.0-45849120146 10.1593/neo.08312
3. Santos E., Martin Zanca D., Reddy E. P., Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 1984 223 4637 661 664 2-s2.0-0021362206
4. Salerno S., Bazan V., Tomasino R. M., Migliavacca M., Labianca R., Zanna I., Gebbia N., Tubiolo C., Grassi N., Russo A., Latteri M. A., La Farina M., Albanese I., Dardanoni G., Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Annals of Oncology 2002 13 9 1438 1446 2-s2.0-0036739336 10.1093/annonc/mdf226
5. Ogino S., Nosho K., Kirkner G. J., Kawasaki T., Meyerhardt J. A., Loda M., Giovannucci E. L., Fuchs C. S., CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009 58 1 90 96 2-s2.0-58249089525 10.1136/gut.2008.155473
6. Pfeifer G. P., Dammann R., Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry 2005 70 5 576 583 2-s2.0-21544483241 10.1007/s10541-005-0151-y
7. Hesson L. B., Cooper W. N., Latif F., The role of RASSF1A methylation in cancer. Disease Markers 2007 23 1-2 73 87 2-s2.0-33847358769
8. Park S. H., Kim J. J., Chung J. S., Lee S. R., Lee G. Y., Kim H. J., Yoo Y. D., RASSF1A suppresses the activated K-Ras-induced oxidative DNA damage. Biochemical and Biophysical Research Communications 2011 408 1 149 153 2-s2.0-79955374780 10.1016/j.bbrc.2011.03.139
9. Donninger H., Vos M. D., Clark G. J., The RASSF1A tumor suppressor. Journal of Cell Science 2007 120 18 3163 3172 2-s2.0-35548987430 10.1242/jcs.010389
10. Burbee D. G., Forgacs E., Zöchbauer-Müller S., Shivakumar L., Fong K., Gao B., Randle D., Kondo M., Virmani A., Bader S., Sekido Y., Latif F., Milchgrub S., Toyooka S., Gazdar A. F., Lerman M. I., Zabarovsky E., White M., Minna J. D., Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. Journal of the National Cancer Institute 2001 93 9 691 699 2-s2.0-0035795676
11. Kuzmin I., Gillespie J. W., Protopopov A., Geil L., Dreijerink K., Yang Y., Vocke C. D., Duh F.-M., Zabarovsky E., Minna J. D., Rhim J. S., Emmert-Buck M. R., Linehan W. M., Lerman M. I., The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Research 2002 62 12 3498 3502 2-s2.0-0037096818
12. Wang T., Liu H., Chen Y., Liu W., Yu J., Wu G., Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. Journal of Experimental and Clinical Cancer Research 2009 28 1, article 160 2-s2.0-76149096516 10.1186/1756-9966-28-160
13. Bhagat R., Chadaga S., Premalata C. S., Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development. Cellular Oncology 2012 35 6 473 479
14. Chen H., Suzuki M., Nakamura Y., Ohira M., Ando S., Iida T., Nakajima T., Nakagawara A., Kimura H., Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer. Oncology Reports 2006 15 5 1281 1285 2-s2.0-33744974059
15. Kee S. K., Lee J. Y., Kim M. J., Lee S. M., Jung Y. W., Kim Y. J., Park J. Y., Bae H. I., Hong H. S., Yun Y. K., Kim S. G., Kim D. S., Hypermethylation of the Ras association domain family 1A (RASSF1A) gene in gallbladder cancer. Molecules and Cells 2007 24 3 364 371 2-s2.0-38349039739
16. Lo P. H. Y., Xie D., Chan K. C., Xu F.-P., Kuzmin I., Lerman M. I., Law S., Chua D., Sham J., Lung M. L., Reduced expression of RASSF1A in esophageal and nasopharyngeal carcinomas significantly correlates with tumor stage. Cancer Letters 2007 257 2 199 205 2-s2.0-35148856846 10.1016/j.canlet.2007.07.018
17. Lee M.-G., Kim H.-Y., Byun D.-S., Lee S.-J., Lee C.-H., Kim J. II, Chang S.-G., Chi S.-G., Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Research 2001 61 18 6688 6692 2-s2.0-0035884193
18. Vos M. D., Ellis C. A., Bell A., Birrer M. J., Clark G. J., Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. Journal of Biological Chemistry 2000 275 46 35669 35672 2-s2.0-0034680870 10.1074/jbc.C000463200
19. Yeo W., Wong W.-L., Wong N., Law B. K., Tse G. M., Zhong S., High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer. Pathology 2005 37 2 125 130 2-s2.0-17844362997 10.1080/00313020500058623
20. Kim D.-H., Kim J. S., Park J.-H., Lee S. K., Ji Y.-I., Kwon Y. M., Shim Y. M., Han J., Park J., Relationship of Ras association domain family 1 methylation and K-Ras mutation in primary non-small cell lung cancer. Cancer Research 2003 63 19 6206 6211 2-s2.0-0141954012
21. Gao B., Xie X.-J., Huang C., Shames D. S., Chen T. T.-L., Lewis C. M., Bian A., Zhang B., Olopade O. I., Garber J. E., Euhus D. M., Tomlinson G. E., Minna J. D., RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Research 2008 68 1 22 25 2-s2.0-39149103745 10.1158/0008-5472.CAN-07-5183
22. Pijnenborg J. M. A., Dam-de Veen G. C., Kisters N., Delvoux B., van Engeland M., Herman J. G., Groothuis P. G., RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer. Annals of Oncology 2007 18 3 491 497 2-s2.0-33847630443 10.1093/annonc/mdl455
23. Azizi E., Kittai A., Kozuch P., Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer. Chemotherapy Research and Practice 2012 2012 15 198197 10.1155/2012/198197
24. Cui X., Shirai Y., Wakai T., Yokoyama N., Hirano S., Hatakeyama K., Aberrant expression of pRb and p16INK4a, alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Human Pathology 2004 35 10 1189 1195 2-s2.0-5444230097 10.1016/j.humpath.2004.06.010
25. Goldstein N. S., Armin M., Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001 92 5 1331 1346
26. Cui X., Wakai T., Shirai Y., Hatakeyama K., Hirano S., Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. Toxicological Sciences 2006 91 2 372 381 2-s2.0-33744827997 10.1093/toxsci/kfj159
27. Miranda E., Destro A., Malesci A., Balladore E., Bianchi P., Baryshnikova E., Franchi G., Morenghi E., Laghi L., Gennari L., Roncalli M., Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. British Journal of Cancer 2006 95 8 1101 1107 2-s2.0-33750211241 10.1038/sj.bjc.6603337
28. Poulogiannis G., Luo F., Arends M. J., RAS signalling in the colorectum in health and disease. Cell Communication and Adhesion 2012 19 1 1 9 2-s2.0-84858808741 10.3109/15419061.2011.649380
29. Spugnardi M., Tommasi S., Dammann R., Pfeifer G. P., Hoon D. S. B., Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Research 2003 63 7 1639 1643 2-s2.0-0037380925
30. Cohen S. J., Cohen R. B., Meropol N. J., Targeting signal transduction pathways in colorectal cancer: more than skin deep. Journal of Clinical Oncology 2005 23 23 5374 5385 2-s2.0-23944469938 10.1200/JCO.2005.02.194
31. Yanagawa N., Tamura G., Oizumi H., Endoh M., Sadahiro M., Motoyama T., Inverse correlation between EGFR mutation and FHIT, RASSFlA and RUNX3 methylation in lung adenocarcinoma: relation with smoking status. Anticancer Research 2011 31 4 1211 1214 2-s2.0-79956115427